Owned by the Association for International Promotion & Study in Tumors (APSIT)
Articles
Page 3 of 72
-
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:158
-
Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:157 -
Retraction Note: Forkhead box (FOX) G1 promotes hepatocellular carcinoma epithelial-Mesenchymal transition by activating Wnt signal through forming T-cell factor-4/Beta-catenin/FOXG1 complex
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:156 -
Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications
Pancreatic ductal adenocarcinoma (PDAC) tends to undergo distant metastasis, especially liver metastasis, leading to a poor prognosis. Metabolic remodelling and epigenetic reprogramming are two important hallm...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:155 -
Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60–70% of event-free survival for localized diseas...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:154 -
Correction: Dehydrodiisoeugenol inhibits colorectal cancer growth by endoplasmic reticulum stress-induced autophagic pathways
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:153 -
Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients
Immune checkpoint blockade (ICB) treatment of hepatocellular carcinoma (HCC) patients with hepatitis B virus (HBV) infection may activate viral-specific T cells to attack HBV infected hepatocytes and thus indu...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:152 -
METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression
Glycolysis is the key hallmark of cancer and maintains malignant tumor initiation and progression. The role of N6-methyladenosine (m6A) modification in glycolysis is largely unknown. This study explored the bi...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:151 -
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer
The incidence of colorectal cancer and cancer death rate are increasing every year, and the affected population is becoming younger. Traditional Chinese medicine therapy has a unique effect in prolonging survi...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:150 -
Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy
Adenosine-to-inosine (A-to-I) editing, a key RNA modification widely found in eukaryotes, is catalyzed by adenosine deaminases acting on RNA (ADARs). Such RNA editing destabilizes endogenous dsRNAs, which are ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:149 -
AXL in cancer: a modulator of drug resistance and therapeutic target
AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. Th...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:148 -
The lncRNA HOTAIR: a pleiotropic regulator of epithelial cell plasticity
The epithelial-to-mesenchymal transition (EMT) is a trans-differentiation process that endows epithelial cells with mesenchymal properties, including motility and invasion capacity; therefore, its aberrant rea...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:147 -
B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma
Invasive adenocarcinoma (IAC), which is typically preceded by minimally invasive adenocarcinoma (MIA), is the dominant pathological subtype of early-stage lung adenocarcinoma (LUAD). Identifying the molecular ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:146 -
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma
Metabolic reprogramming is a well-known marker of cancer, and it represents an early event during hepatocellular carcinoma (HCC) development. The recent approval of several molecular targeted agents has revolu...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:145 -
Retraction Note: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)- methyladenosine modification of MT-RNR1
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:144 -
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Hypoxia-induced glycogen turnover is implicated in cancer proliferation and therapy resistance. Triple-negative breast cancers (TNBCs), characterized by a hypoxic tumor microenvironment, respond poorly to ther...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:143 -
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer
Cuproptosis and ferroptosis are the two newly defined metal-related regulated cell death. However, the crosstalk between cuproptosis and ferroptosis is obscure.
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:142 -
Correction: Tobacco smoke induced hepatic cancer stem cell-like properties through IL-33/p38 pathway
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:141 -
Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR
The transmembrane receptor Kremen2 has been reported to participate in the tumorigenesis and metastasis of gastric cancer. However, the role of Kremen2 in non-small cell lung cancer (NSCLC) and the underlying ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:140 -
Retraction Note: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:139 -
CREBZF mRNA nanoparticles suppress breast cancer progression through a positive feedback loop boosted by circPAPD4
Breast cancer (BC) negatively impacts the health of women worldwide. Circular RNAs (circRNAs) are a group of endogenous RNAs considered essential regulatory factor in BC tumorigenesis and progression. However,...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:138 -
Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia
Immune checkpoint blockade (ICB) elicits a strong and durable therapeutic response, but its application is limited by disparate responses and its associated immune-related adverse events (irAEs). Previously, i...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:132 -
Disulfidptosis: a new form of programmed cell death
Disulfidptosis, a new form of cell death triggered by disulfide stress, is characterized by the collapse of cytoskeleton proteins and F-actin due to the intracellular accumulation of disulfides. This discovery...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:137 -
Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer
Increasing evidence indicates that the tumor microenvironment (TME) is a crucial determinant of cancer progression. However, the clinical and pathobiological significance of stromal signatures in the TME, as a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:136 -
Correction: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:135 -
Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Large-scale metabolomic data have associated metabolic alterations with the pathogenesis and progression of renal carcinoma a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:134 -
Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation
Efforts to precisely assess tumor-specific T-cell immune responses still face major challenges, and the potential molecular mechanisms mediating hepatocellular carcinoma (HCC) microenvironment imbalance after ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:133 -
Harnessing cancer stem cell-derived exosomes to improve cancer therapy
Cancer stem cells (CSCs) are the key “seeds” for tumor initiation and development, metastasis, and recurrence. Because of the function of CSCs in tumor development and progression, research in this field has i...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:131 -
New insights into the ambivalent role of YAP/TAZ in human cancers
Hippo signaling was first identified in Drosophila as a key controller of organ size by regulating cell proliferation and anti-apoptosis. Subsequent studies have shown that this pathway is highly conserved in ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:130 -
Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling
Emerging studies have identified chronic psychological stress as an independent risk factor influencing breast cancer growth and metastasis. However, the effects of chronic psychological stress on pre-metasta...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:129 -
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:128 -
Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1
Ferroptosis has been linked to tumor progression and resistance to antineoplastic therapy. Long noncoding RNA (lncRNA) exerts a regulatory role in various biological processes of tumor cells, while the functio...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:127 -
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
High grade serous ovarian cancer (HGSOC) is highly lethal, partly due to chemotherapy resistance and limited availability of targeted approaches. Cyclin dependent kinases 12 and 13 (CDK12/13) are promising the...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:126 -
CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma
Increasing evidence shows that circular RNAs (circRNAs), a novel class of noncoding RNAs, play a crucial role in the development of cancers, including intrahepatic cholangiocarcinoma (iCCA). Nevertheless, thei...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:125 -
Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:124 -
Retraction Note: Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:123 -
Pancreatic cancer stemness: dynamic status in malignant progression
Pancreatic cancer (PC) is one of the most aggressive malignancies worldwide. Increasing evidence suggests that the capacity for self-renewal, proliferation, and differentiation of pancreatic cancer stem cells ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:122 -
CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis
The repressor element-1 silencing transcription factor (REST), a master transcriptional repressor, is essential for maintenance, self-renewal, and differentiation in neuroblastoma. An elevated expression of RE...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:121 -
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity
MET-driven acquired resistance is emerging with unanticipated frequency in patients relapsing upon molecular therapy treatments. However, the determination of MET amplification remains challenging using both stan...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:120 -
Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition
Prostate Cancer (PCa) represents one of the most commonly diagnosed neoplasms in men and is associated with significant morbidity and mortality. Therapy resistance and significant side effects of current treat...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:119 -
Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:118 -
Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribut...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:117 -
Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression
Bronchial premalignant lesions (PMLs) are composed primarily of cells resembling basal epithelial cells of the airways, which through poorly understood mechanisms have the potential to progress to lung squamou...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:116 -
Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
Patients with colorectal metastatic disease have a poor prognosis, limited therapeutic options, and frequent development of resistance. Strategies based on tumor-derived organoids are a powerful tool to assess...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:115 -
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Current clinical and observational evidence supports the EXTREME regimen as one of the standards of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) followed by the ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:114 -
Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Methylation of the p16 promoter resulting in epigenetic gene silencing—known as p16 epimutation—is frequently found in human colorectal cancer and is also common in normal-appearing colonic mucosa of aging indivi...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:113 -
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA re...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:112 -
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance.
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:111 -
Loss of Ufl1/Ufbp1 in hepatocytes promotes liver pathological damage and carcinogenesis through activating mTOR signaling
Ufm1-specific ligase 1 (Ufl1) and Ufm1-binding protein 1 (Ufbp1), as putative targets of ubiquitin-fold modifier 1 (Ufm1), have been implicated in several pathogenesis-related signaling pathways. However, litt...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:110 -
miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1
We have previously reported that extracellular vesicles (EVs) derived from osteoblastic, osteoclastic and mixed prostate cancer cells promote osteoclast differentiation and inhibit osteoblast differentiation v...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:109
-
-
-
Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
-
2022 Citation Impact
11.3 - 2-year Impact Factor
11.5 - 5-year Impact Factor
1.870 - SNIP (Source Normalized Impact per Paper)
2.413 - SJR (SCImago Journal Rank)2022 Speed
5 days submission to first editorial decision for all manuscripts (Median)
97 days submission to accept (Median)2022 Usage
2,694,347 downloads
4,666 Altmetric mentions